Институт стволовых клеток человека logo
Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Kennzahlen 2023-2006 | ISKJ

Kurzer Überblick über die Finanzkennzahlen von Институт стволовых клеток человека

Aktuelle Werte werden mit der eigenen Fünfjahreshistorie des Unternehmens für 2019–2023 verglichen.

Der Bewertungsvergleich verwendet P/E 42,36x (Median 42,36x), EV/EBITDA 22,69x (Median 22,69x), P/S 5,23x (Median 5,23x). Die Kennzahlen liegen nahe ihrer Vergleichsbasis, mit durchschnittlich 0% Abweichung von den Fünfjahresmedianen.

Der Kehrwert des KGV ergibt eine Gewinnrendite von 2,4%. Das ist keine Dividendenrendite, sondern Gewinn relativ zum Marktpreis.

Die Renditekennzahlen am Periodenende sind ROE 33,7%, ROA 6,6%, ROCE 13,9%. Die fundamentale Effizienz ist ausgewogen: Rentabilität stützt die Bewertung, ersetzt aber kein weiteres Wachstum.

Das aktuelle PEG beträgt 0,17x; der Markt zahlt vergleichsweise wenig je Einheit erwarteten Wachstums.

Die Liquidität ist gesund, mit Current Ratio 1,99x und Quick Ratio 1,59x.

Bei Debt/Equity von 1,57x werden Zinsen nur 1,64x gedeckt. Der Hebel ist angespannt.

Der Cash Conversion Cycle sank von 200 Tage auf 178,7 Tage beziehungsweise um 21,3 Tage. Working Capital kehrt schneller zurück.

Einordnung der Multiplikatoren

Die Marktbewertung von Институт стволовых клеток человека liegt nahe der historischen Norm, während Qualitätskennzahlen kein extremes Signal senden.

Kennzahlen Jährlich Институт стволовых клеток человека

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

Price Earnings Ratio, P/E

42.36 145.3 274.0 27.68 11.52 -17.45 -8.41 -12.16 -15.21 -62.53 99.14 -6.8 45.37 114.89 19.64 131.64 144.8 -

Price Sales Ratio, P/S

5.23 5.89 7.78 2.64 1.17 0.93 1.74 3.47 2.52 2.3 3.48 3.22 3.17 4.01 5.94 9.17 13.62 -

Price To Book Ratio, P/B

14.29 19.65 39.15 14.73 9.87 22.09 16.84 8.8 2.72 2.43 4.15 1.55 1.03 4.0 4.49 56.18 71.8 -

Price Earnings To Growth Ratio, PEG

0.17 5.55 -3.94 1.25 -0.03 0.26 1.13 -0.11 -0.05 0.33 -0.9 0.04 0.02 -1.33 0.03 13.16 - -

Operating Cash Flow Per Share

4.69 2.53 3.51 0.72 2.34 0.26 -0.26 0.48 0.06 0.51 1.1 -0.35 0.59 0.0 0.73 0.5 0.08 -

Free Cash Flow Per Share

2.48 0.97 1.59 -0.42 -0.27 -0.21 -3.1 -0.41 -0.2 0.07 0.64 -1.02 0.16 -0.14 0.55 0.19 -0.04 -

Cash Per Share

6.17 3.25 2.73 1.7 2.54 2.73 1.72 5.04 2.8 2.77 1.47 0.36 0.24 1.17 2.57 0.07 0.09 -

Payout Ratio

- - - - - - - -0.19 - - - - - 1.12 0.19 0.5 - -

Dividend Yield

- - - - - - - 0.02 - - - - - 0.01 0.01 0.0 - -

Current Ratio

1.99 1.74 1.77 1.04 1.05 1.15 0.71 1.18 0.86 0.89 0.66 0.82 1.02 1.47 2.41 0.41 1.0 0.95

Quick Ratio

1.59 1.18 1.11 0.62 0.69 0.81 0.48 1.04 0.74 0.76 0.62 0.73 0.88 1.38 2.36 0.35 0.91 0.87

Cash Ratio

0.97 0.51 0.52 0.19 0.18 0.16 0.19 0.6 0.12 0.19 0.06 0.13 0.17 0.7 2.0 0.09 0.23 0.12

Days Of Sales Outstanding, DSO

21.82 - - - - - - - - - - 29.43 - - - - - -

Days Of Inventory Outstanding, DIO

205.28 314.65 309.57 274.8 383.57 632.62 489.26 348.28 400.96 630.98 334.6 187.13 188.64 1451.81 270.24 537.47 1887.45 -

Days Of Payables Outstanding, DPO

48.44 93.94 128.87 114.55 183.58 557.57 287.45 475.79 148.59 115.17 358.41 166.17 347.4 942.75 819.86 8023.06 19236.82 -

Operating Cycle

227.1 314.65 309.57 274.8 383.57 632.62 489.26 348.28 400.96 630.98 334.6 216.56 188.64 1451.81 270.24 537.47 1887.45 -

Cash Conversion Cycle

178.66 220.71 180.69 160.24 199.99 75.05 201.82 -127.5 252.37 515.81 -23.81 50.39 -158.76 509.06 -549.62 -7485.59 -17349.37 -

Gross Profit Margin

0.71 0.77 0.75 0.71 0.8 0.88 0.81 0.83 0.85 0.92 0.96 0.9 0.89 0.99 0.97 0.98 0.99 -

Operating Profit Margin

0.2 0.1 0.08 0.14 0.22 0.18 -0.12 -0.37 -0.31 -0.14 0.1 -0.04 0.06 0.04 0.19 0.06 0.11 -

Pretax Profit Margin

0.15 0.03 0.02 0.09 0.12 -0.08 -0.26 -0.38 -0.19 0.0 0.07 -0.45 0.07 0.05 0.34 0.09 0.12 -

Net Profit Margin

0.12 0.04 0.03 0.1 0.1 -0.05 -0.21 -0.29 -0.17 -0.04 0.04 -0.47 0.07 0.03 0.3 0.07 0.09 -

Effective Tax Rate

0.08 0.21 -0.14 -0.11 -0.1 0.66 0.14 0.13 -0.04 104.76 0.39 -0.05 -0.09 0.32 0.12 0.22 0.26 -

Return On Assets, ROA

0.07 0.02 0.02 0.07 0.06 -0.03 -0.1 -0.11 -0.06 -0.02 0.02 -0.15 0.02 0.02 0.16 0.1 0.17 -

Return On Equity, ROE

0.34 0.14 0.14 0.53 0.86 -1.27 -2.0 -0.72 -0.18 -0.04 0.04 -0.23 0.02 0.03 0.23 0.43 0.5 -

Return On Capital Employed, ROCE

0.14 0.07 0.07 0.15 0.2 0.16 -0.12 -0.26 -0.23 -0.12 0.11 -0.01 0.02 0.04 0.14 0.36 0.53 -

Net Income Per Ebt

0.8 1.57 1.14 1.11 0.83 0.64 0.81 0.74 0.85 -82.46 0.54 1.05 0.95 0.71 0.89 0.79 0.77 -

Ebt Per Ebit

0.77 0.26 0.32 0.64 0.56 -0.46 2.19 1.04 0.63 -0.0 0.64 12.05 1.16 1.33 1.83 1.38 1.1 -

Ebit Per Revenue

0.2 0.1 0.08 0.14 0.22 0.18 -0.12 -0.37 -0.31 -0.14 0.1 -0.04 0.06 0.04 0.19 0.06 0.11 -

Debt Ratio

0.31 0.41 0.36 0.32 0.3 0.33 0.39 0.33 0.14 0.12 0.18 0.15 0.01 0.0 0.0 0.05 - -

Debt Equity Ratio

1.57 2.44 2.63 2.51 4.3 13.86 8.09 2.25 0.4 0.29 0.37 0.23 0.01 0.0 0.0 0.19 - -

Long Term Debt To Capitalization

0.46 0.64 0.68 0.47 0.59 0.92 0.88 0.67 0.08 - 0.09 0.09 0.0 - - - - -

Total Debt To Capitalization

0.61 0.71 0.72 0.72 0.81 0.93 0.89 0.69 0.29 0.23 0.27 0.18 0.01 0.0 0.0 0.16 - -

Interest Coverage

- 1.64 1.82 3.66 4.34 3.88 -1.89 -5.31 -11.05 -4.29 2.31 -2.17 40.2 23.51 76.98 28.88 183.43 -

Cash Flow To Debt Ratio

0.55 0.26 0.46 0.11 0.41 0.05 -0.05 0.1 0.04 0.39 0.64 -0.18 4.03 7.67 5492.12 10.12 - -

Company Equity Multiplier

5.08 6.0 7.4 7.78 14.17 41.62 20.57 6.76 2.89 2.38 2.07 1.53 1.21 1.53 1.41 4.13 2.98 3.15

Receivables Turnover

16.72 - - - - - - - - - - 12.4 - - - - - -

Payables Turnover

7.53 3.89 2.83 3.19 1.99 0.65 1.27 0.77 2.46 3.17 1.02 2.2 1.05 0.39 0.45 0.05 0.02 -

Inventory Turn Over

1.78 1.16 1.18 1.33 0.95 0.58 0.75 1.05 0.91 0.58 1.09 1.95 1.93 0.25 1.35 0.68 0.19 -

Fixed Asset Turnover

4.33 4.05 4.14 3.28 2.2 2.33 1.75 2.55 3.22 3.25 3.57 4.78 7.08 5.38 4.38 3.7 6.26 -

Asset Turnover

0.54 0.56 0.68 0.72 0.6 0.57 0.47 0.38 0.37 0.45 0.58 0.32 0.27 0.65 0.54 1.48 1.77 -

Operating Cash Flow Sales Ratio

0.32 0.19 0.24 0.05 0.21 0.03 -0.04 0.09 0.01 0.11 0.2 -0.08 0.16 0.0 0.3 0.32 0.08 -

Free Cash Flow Operating Cash Flow Ratio

0.53 0.38 0.45 -0.59 -0.12 -0.82 11.83 -0.86 -3.2 0.14 0.58 2.89 0.28 -73.52 0.75 0.37 -0.5 -

Cash Flow Coverage Ratios

0.55 0.26 0.46 0.11 0.41 0.05 -0.05 0.1 0.04 0.39 0.64 -0.18 4.03 7.67 5492.12 10.12 - -

Short Term Coverage Ratios

1.97 2.06 1390.1 0.3 1.27 0.38 -0.4 0.93 0.05 0.39 0.91 -0.3 4.34 7.67 5492.12 10.12 - -

Capital Expenditure Coverage Ratio

2.13 1.62 1.83 0.63 0.9 0.55 -0.09 0.54 0.24 1.16 2.39 -0.53 1.38 0.01 4.01 1.6 0.67 -

Dividend Paid And Capex Coverage Ratio

2.13 1.62 1.83 0.63 0.9 0.55 -0.09 0.41 0.24 1.16 2.39 -0.53 1.38 0.01 2.25 1.36 0.67 -

Dividend Payout Ratio

- - - - - - - -0.19 - - - - - 1.12 0.19 0.5 - -

Price To Free Cash Flows Ratio, P/FCF

31.03 79.42 72.09 -90.18 -47.45 -37.51 -3.71 -43.83 -53.32 153.57 30.4 -13.26 71.12 -91.33 26.39 77.5 -357.13 -

Price To Operating Cash Flows Ratio, P/OCF

16.45 30.42 32.73 53.13 5.55 30.74 -43.9 37.55 170.38 21.58 17.69 -38.3 19.71 6714.78 19.81 29.06 177.07 -

Price Cash Flow Ratio, P/CF

16.45 30.42 32.73 53.13 5.55 30.74 -43.9 37.55 170.38 21.58 17.69 -38.3 19.71 6714.78 19.81 29.06 177.07 -

Enterprise Value Multiple, EV

22.69 48.68 59.57 15.55 6.45 7.09 -431.98 -14.34 -14.4 22.99 24.41 105.48 32.0 44.55 13.32 80.54 99.64 -

Price Fair Value, P/FV

14.29 19.65 39.15 14.73 9.87 22.09 16.84 8.8 2.72 2.43 4.15 1.55 1.03 4.0 4.49 56.18 71.8 -

Alle Zahlen in RUB-Währung

Kennzahlen Vierteljährlich Институт стволовых клеток человека

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q3

Price Earnings Ratio, P/E

34.3 K 34.3 K 21.2 K 21.2 K 89.8 K 89.8 K 162 K 162 K 133 K 154 K 196 -484 K 24.9 71.1 K 24.8 3.07 M 40.9 6.05 K 0.003 16.8 K 6.54 K 6.76 K -4.43 K -5.12 K 10.7 K 10.2 K -2.59 9.9 -9.21 K -13.6 K -53.8 -8.22 - -68.5 -5.77 K -5.66 K 21.4 K 21.3 K -8.85 K -9.84 K 15.9 K 5.34 -28 K -25.7 K - 12.3 -

Price Sales Ratio, P/S

15.3 K 15.3 K 15.5 K 15.5 K 18.4 K 18.4 K 22.2 K 22.2 K 25.6 K 29.6 K 13.5 25.1 K 5.01 10.1 K 4.99 8.13 K 2.98 3.87 K 0.002 4.94 K 3.49 K 3.6 K 3.4 K 3.93 K 4.86 K 4.63 K 6.07 7.84 8.04 9.39 12.9 16.6 - 21.3 9.87 9.68 9.23 K 9.18 K 8.91 9.91 12.2 K 10.9 14.3 K 13.2 K - 8.59 -

Price To Book Ratio, P/B

13.2 K 13.2 K 11.6 K 11.6 K 15 K 15 K 20.1 K 20.1 K 24.1 K 27.8 K 35.9 K 33.3 K 12.5 K 12.6 K 14.3 K 13.2 K 8.7 K 4.05 K 9.87 10 K 4.37 K 4.52 K 22.1 K 25.5 K 6.13 K 5.84 K 16.8 7.31 8.22 K 8.06 K 8.8 8.57 - 7.1 2.72 K 2.67 K 1.97 K 1.96 K 2.43 K 2.7 K 2.38 K 1.43 4.15 K 1.7 K - 1.41 -

Price Earnings To Growth Ratio, PEG

- -1.03 K - 60.5 - 898 - - - -1.54 K - 4.84 K 0.0 -711 - -30.7 K 0.001 -60.5 0.0 -503 - -38.6 - 17.1 - -102 0.006 -0.0 - 136 0.633 0.325 - -0.004 - 9.43 - -160 - 39.4 -159 -0.0 - - - - -

Operating Cash Flow Per Share

0.001 0.001 0.003 0.003 0.0 0.0 0.001 0.001 0.0 0.0 2.71 0.001 0.51 0.0 - 0.001 - -0.0 - 0.001 0.0 0.0 -0.0 -0.0 0.001 0.001 0.54 -0.173 -0.0 -0.0 1.88 -1.11 - -0.316 0.0 0.0 -0.0 -0.0 -0.0 - 0.0 - 0.0 - - - -

Free Cash Flow Per Share

0.0 0.0 0.002 0.002 -0.0 -0.0 0.001 0.001 -0.0 -0.0 0.763 0.001 -0.225 -0.0 - 0.001 - -0.001 - -0.0 0.0 0.0 -0.0 -0.0 -0.0 -0.0 0.323 -0.854 -0.002 -0.001 1.2 -1.2 - -0.316 0.0 0.0 -0.0 -0.0 -0.0 - 0.0 - 0.0 - - - -

Cash Per Share

0.005 0.005 0.008 0.008 0.005 0.005 0.003 0.003 0.001 0.001 0.003 0.002 0.001 0.001 0.002 0.001 0.003 0.002 2.54 0.002 0.002 0.002 0.003 0.003 0.003 0.003 1.72 2.66 0.004 0.006 5.04 4.75 - 2.39 0.003 0.003 0.003 0.002 0.002 0.002 0.003 2.62 0.001 0.001 - 1.16 -

Current Ratio

1.88 1.88 1.99 1.99 2.09 2.09 1.74 1.74 1.98 1.98 1.77 1.77 1.32 1.32 1.04 1.04 1.41 1.41 1.05 1.05 1.22 1.22 1.15 1.15 0.804 0.804 0.705 0.934 0.946 1.27 1.18 1.28 0.699 0.697 0.863 0.863 0.953 0.953 0.895 0.895 0.939 0.852 0.662 0.783 1.05 0.826 0.895

Quick Ratio

1.41 1.41 1.59 1.59 1.61 1.61 1.18 1.18 1.21 1.21 1.11 1.11 0.689 0.689 0.616 0.616 0.829 0.829 0.691 0.691 0.848 0.848 0.814 0.814 0.624 0.624 0.483 0.775 0.808 1.14 1.04 1.17 0.55 0.697 0.738 0.738 0.802 0.802 0.756 0.756 0.895 0.817 0.616 0.727 0.923 0.768 0.831

Cash Ratio

0.686 0.686 0.971 0.971 0.796 0.796 0.51 0.51 0.202 0.202 0.519 0.519 0.12 0.12 0.193 0.193 0.344 0.344 0.184 0.184 0.143 0.143 0.156 0.156 0.135 0.135 0.191 0.235 0.367 0.668 0.598 0.694 0.053 0.069 0.121 0.121 0.161 0.161 0.194 0.194 0.276 0.142 0.056 0.02 0.224 0.016 0.088

Days Of Sales Outstanding, DSO

20.8 20.8 19.7 19.7 - 30.1 - 19.8 - 23 0.012 24 0.016 31.6 - 25.7 - 21.5 - 24.7 - 23 - 22.4 - 30.4 - - - 0.053 - 34.6 - - - 0.027 - 30.7 0.018 0.018 - - 49.2 - - - -

Days Of Inventory Outstanding, DIO

244 244 171 171 239 239 153 153 212 212 0.05 184 0.056 206 0.052 130 0.051 731 0.061 250 352 352 476 476 265 265 279 520 198 142 291 170 131 - 129 129 207 207 182 182 74.2 15.3 101 107 - 34.3 -

Days Of Payables Outstanding, DPO

27.1 27.1 40.4 40.4 161 36 45.5 23.1 104 51 0.021 27 0.02 73 0.022 19.7 0.02 87.2 0.029 59.3 168 168 419 276 215 179 164 408 291 188 397 124 110 128 47.6 38 40.7 20.4 14.2 14.2 92.8 315 40.2 1.29 K - 384 -

Operating Cycle

264 264 191 191 239 269 153 172 212 235 0.062 208 0.072 238 0.052 156 0.051 753 0.061 274 352 375 476 498 265 296 279 520 198 142 291 205 131 - 129 129 207 238 182 182 74.2 15.3 150 107 - 34.3 -

Cash Conversion Cycle

237 237 150 150 78.3 233 107 149 109 184 0.041 181 0.052 165 0.03 136 0.031 665 0.032 215 184 207 56.4 223 50.5 117 115 112 -92.6 -45.8 -106 80.5 21.4 -128 80.9 90.6 167 218 168 168 -18.6 -299 110 -1.18 K - -349 -

Gross Profit Margin

0.75 0.75 0.681 0.681 0.736 0.736 0.572 0.572 0.629 0.629 0.296 0.616 0.274 0.602 0.274 0.489 0.244 0.854 0.435 0.724 0.797 0.797 0.852 0.852 0.756 0.756 0.719 0.899 1.0 1.0 0.811 0.731 0.606 0.865 1.0 1.0 0.688 0.688 1.0 1.0 0.796 0.331 0.868 0.868 - 0.647 -

Operating Profit Margin

0.223 0.223 0.228 0.228 0.169 0.169 0.077 0.077 0.122 0.122 0.044 0.086 0.078 0.118 0.093 0.096 0.075 0.303 0.213 0.239 0.189 0.189 0.343 0.343 -0.011 -0.011 -0.043 0.03 -0.0 -0.0 -0.37 -0.755 -0.425 0.041 -0.0 -0.0 -0.121 -0.121 -0.0 -0.0 -0.082 0.031 0.002 0.002 - 0.426 -

Pretax Profit Margin

0.136 0.136 0.225 0.225 0.07 0.07 -0.0 -0.0 0.057 0.057 0.018 0.013 0.043 0.039 0.043 0.02 0.021 0.178 0.178 0.083 0.166 0.166 -0.231 -0.231 0.093 0.093 -0.595 0.124 -0.0 -0.0 -0.176 -0.73 -0.575 -0.088 -0.0 -0.0 0.116 0.116 -0.0 -0.0 0.24 0.668 -0.115 -0.115 - 0.228 -

Net Profit Margin

0.112 0.112 0.183 0.183 0.051 0.051 0.034 0.034 0.048 0.048 0.017 -0.013 0.05 0.035 0.05 0.001 0.018 0.16 0.204 0.074 0.133 0.133 -0.192 -0.192 0.113 0.113 -0.585 0.198 -0.0 -0.0 -0.06 -0.506 -0.514 -0.078 -0.0 -0.0 0.108 0.108 -0.0 -0.0 0.192 0.511 -0.128 -0.128 - 0.175 -

Effective Tax Rate

0.022 0.022 0.056 0.056 0.17 0.17 -55.1 -55.1 0.017 0.017 0.018 0.025 -0.181 199 -0.181 0.139 0.135 146 -0.146 292 0.017 0.017 -0.359 -0.359 235 235 0.067 -0.625 -0.075 -0.01 0.339 0.197 -0.006 0.121 -0.02 -0.02 0.214 0.214 -0.12 -0.12 0.282 0.235 -0.174 -0.174 - 0.233 -

Return On Assets, ROA

0.017 0.017 0.027 0.027 0.007 0.007 0.005 0.005 0.007 0.007 6.2 -0.002 18.7 0.007 18.5 0.0 7.24 0.023 66 0.012 0.018 0.018 -0.03 -0.03 0.015 0.015 -0.079 0.024 -0.023 -0.018 -0.006 -0.042 -0.074 -0.009 -0.041 -0.041 0.01 0.01 -0.029 -0.029 0.02 0.045 -0.018 -0.012 - 0.02 -

Return On Equity, ROE

0.096 0.096 0.137 0.137 0.042 0.042 0.031 0.031 0.045 0.045 45.9 -0.017 125 0.044 144 0.001 53.2 0.168 934 0.15 0.167 0.167 -1.25 -1.25 0.143 0.143 -1.62 0.185 -0.223 -0.148 -0.041 -0.261 -0.278 -0.026 -0.118 -0.118 0.023 0.023 -0.069 -0.069 0.037 0.067 -0.037 -0.017 - 0.029 -

Return On Capital Employed, ROCE

0.042 0.042 0.043 0.043 0.028 0.028 0.014 0.014 0.022 0.022 20.3 0.02 39.6 0.03 54.1 0.032 41.9 0.061 106 0.059 0.036 0.036 0.085 0.085 -0.003 -0.003 -0.012 0.006 -0.033 -0.059 -0.069 -0.108 -0.138 0.01 -0.093 -0.093 -0.019 -0.019 -0.042 -0.042 -0.014 0.004 0.0 0.0 - 0.064 -

Net Income Per Ebt

0.82 0.82 0.816 0.816 0.734 0.734 -173 -173 0.85 0.85 0.982 -1.02 1.18 0.914 1.18 0.032 0.865 0.899 1.15 0.885 0.803 0.803 0.83 0.83 1.21 1.21 0.983 1.6 0.846 0.68 0.34 0.693 0.893 0.879 0.871 0.871 0.928 0.928 1.12 1.12 0.8 0.765 1.11 1.11 - 0.767 -

Ebt Per Ebit

0.609 0.609 0.984 0.984 0.415 0.415 -0.003 -0.003 0.463 0.463 0.395 0.148 0.545 0.328 0.458 0.213 0.281 0.587 0.833 0.349 0.877 0.877 -0.674 -0.674 -8.84 -8.84 13.9 4.18 1.51 0.797 0.475 0.966 1.35 -2.13 1.01 1.01 -0.96 -0.96 1.12 1.12 -2.93 21.4 -74.9 -74.9 - 0.535 -

Ebit Per Revenue

0.223 0.223 0.228 0.228 0.169 0.169 0.077 0.077 0.122 0.122 0.044 0.086 0.078 0.118 0.093 0.096 0.075 0.303 0.213 0.239 0.189 0.189 0.343 0.343 -0.011 -0.011 -0.043 0.03 -0.0 -0.0 -0.37 -0.755 -0.425 0.041 -0.0 -0.0 -0.121 -0.121 -0.0 -0.0 -0.082 0.031 0.002 0.002 - 0.426 -

Debt Ratio

0.315 0.315 0.309 0.309 0.345 0.345 0.407 0.407 0.356 0.356 0.355 0.355 0.318 0.318 0.323 0.323 0.329 0.329 0.303 0.303 0.364 0.364 0.333 0.333 0.36 0.36 0.393 0.403 0.4 0.393 0.333 0.396 0.099 0.142 0.138 0.138 0.139 0.139 0.123 0.123 0.161 0.098 0.177 0.121 0.124 0.143 0.111

Debt Equity Ratio

1.82 1.82 1.57 1.57 2.13 2.13 2.44 2.44 2.25 2.25 2.63 2.63 2.14 2.14 2.51 2.51 2.41 2.41 4.3 3.83 3.38 3.38 13.9 13.9 3.47 3.47 8.09 3.13 3.94 3.28 2.25 2.43 0.368 0.413 0.399 0.399 0.329 0.329 0.292 0.292 0.3 0.146 0.367 0.172 0.175 0.21 0.156

Long Term Debt To Capitalization

0.503 0.503 0.461 0.461 0.606 0.606 0.638 0.638 0.647 0.647 0.678 0.678 0.473 0.473 0.474 0.474 0.496 0.496 0.593 0.564 0.69 0.69 0.923 0.923 0.744 0.744 0.876 0.737 0.781 0.746 0.667 0.66 0.067 0.063 0.079 0.079 0.067 0.067 - - 0.055 0.043 0.095 0.055 0.063 0.082 0.051

Total Debt To Capitalization

0.646 0.646 0.611 0.611 0.68 0.68 0.709 0.709 0.693 0.693 0.724 0.724 0.681 0.681 0.715 0.715 0.707 0.707 0.811 0.793 0.772 0.772 0.933 0.933 0.777 0.777 0.89 0.758 0.798 0.766 0.692 0.709 0.269 0.292 0.285 0.285 0.248 0.248 0.226 0.226 0.231 0.127 0.268 0.147 0.149 0.173 0.135

Interest Coverage

- - - - - - - - - - 0.779 - 1.55 - 1.84 - 1.39 - 5.97 - - - - - - - -0.727 0.461 - - -2.33 -21.9 -11.9 1.07 - - - - - - - 0.871 - - - 11.4 -

Cash Flow To Debt Ratio

0.072 0.072 0.243 0.243 0.032 0.032 0.104 0.104 0.038 0.038 323 0.184 77.8 0.056 - 0.127 - -0.067 - 0.18 0.029 0.029 -0.082 -0.082 0.1 0.1 0.098 -0.031 -0.046 -0.062 0.407 -0.213 0.024 -0.204 0.216 0.216 -0.192 -0.192 -0.142 - 0.247 - 0.058 - - - -

Company Equity Multiplier

5.8 5.8 5.08 5.08 6.18 6.18 6 6 6.33 6.33 7.4 7.4 6.72 6.72 7.78 7.78 7.34 7.34 14.2 12.6 9.29 9.29 41.6 41.6 9.65 9.65 20.6 7.77 9.86 8.34 6.76 6.14 3.73 2.92 2.89 2.89 2.37 2.37 2.38 2.38 1.86 1.49 2.07 1.42 1.41 1.47 1.41

Receivables Turnover

4.33 4.33 4.57 4.57 - 2.99 - 4.55 - 3.91 7.52 K 3.75 5.68 K 2.85 - 3.5 - 4.19 - 3.65 - 3.91 - 4.01 - 2.96 - - - 1.68 K - 2.6 - - - 3.37 K - 2.94 4.9 K 4.9 K - - 1.83 - - - -

Payables Turnover

3.32 3.32 2.23 2.23 0.56 2.5 1.98 3.9 0.868 1.77 4.29 K 3.34 4.5 K 1.23 4.15 K 4.56 4.58 K 1.03 3.1 K 1.52 0.537 0.537 0.215 0.327 0.419 0.504 0.549 0.221 0.309 0.479 0.227 0.724 0.82 0.704 1.89 2.37 2.21 4.42 6.34 6.34 0.97 0.286 2.24 0.07 - 0.235 -

Inventory Turn Over

0.369 0.369 0.526 0.526 0.376 0.376 0.59 0.59 0.424 0.424 1.79 K 0.488 1.59 K 0.437 1.73 K 0.691 1.77 K 0.123 1.48 K 0.361 0.256 0.256 0.189 0.189 0.339 0.339 0.322 0.173 0.454 0.634 0.309 0.529 0.686 - 0.7 0.7 0.434 0.434 0.494 0.494 1.21 5.88 0.891 0.844 - 2.62 -

Fixed Asset Turnover

1.01 1.01 1.18 1.18 1.03 1.03 1.1 1.1 0.952 0.952 2.19 K 1.09 1.82 K 0.91 1.69 K 0.955 1.77 K 0.636 1.19 K 0.594 0.484 0.484 0.635 0.635 0.546 0.546 0.503 0.444 395 730 0.686 0.913 1.17 1.03 823 823 0.758 0.758 838 838 1.06 1 0.869 0.99 - 1.23 -

Asset Turnover

0.149 0.149 0.147 0.147 0.132 0.132 0.151 0.151 0.149 0.149 359 0.18 371 0.186 368 0.209 398 0.143 324 0.161 0.135 0.135 0.156 0.156 0.131 0.131 0.135 0.12 104 103 0.101 0.084 0.145 0.115 95.4 95.4 0.09 0.09 115 115 0.105 0.088 0.14 0.091 - 0.111 -

Operating Cash Flow Sales Ratio

0.152 0.152 0.512 0.512 0.084 0.084 0.28 0.28 0.091 0.091 0.319 0.364 0.067 0.096 - 0.196 - -0.154 - 0.339 0.079 0.079 -0.174 -0.174 0.275 0.275 0.285 -0.103 -0.0 -0.0 1.34 -1.01 0.016 -0.253 0.0 0.0 -0.296 -0.296 -0.0 - 0.381 - 0.074 - - - -

Free Cash Flow Operating Cash Flow Ratio

0.481 0.481 0.637 0.637 -0.249 -0.249 0.777 0.777 -1.06 -1.06 0.281 0.562 -0.442 -0.004 - 0.703 - 1.7 - -0.084 0.735 0.735 0.093 0.093 -0.127 -0.127 0.598 4.94 7.55 1.56 0.637 1.08 -3.98 1 0.747 0.747 1.15 1.15 1.84 - 0.859 - 2.22 - - - -

Cash Flow Coverage Ratios

0.072 0.072 0.243 0.243 0.032 0.032 0.104 0.104 0.038 0.038 323 0.184 77.8 0.056 - 0.127 - -0.067 - 0.18 0.029 0.029 -0.082 -0.082 0.1 0.1 0.098 -0.031 -0.046 -0.062 0.407 -0.213 0.024 -0.204 0.216 0.216 -0.192 -0.192 -0.142 - 0.247 - 0.058 - - - -

Short Term Coverage Ratios

0.328 0.328 0.867 0.867 0.307 0.307 0.807 0.807 - - 985 K 563 251 0.18 - 0.347 - -0.206 - 0.552 0.427 0.427 -0.603 -0.603 0.626 0.626 0.828 -0.304 -0.493 -0.597 3.63 -1.05 0.03 -0.244 0.275 0.275 -0.246 -0.246 -0.143 - 0.311 - 0.083 - - - -

Capital Expenditure Coverage Ratio

1.93 1.93 2.75 2.75 0.801 0.801 4.49 4.49 0.486 0.486 1.39 2.28 0.693 0.996 - 3.37 - -1.43 - 0.922 3.78 3.78 -1.1 -1.1 0.887 0.887 2.49 -0.254 -0.153 -1.77 2.75 -12.2 0.201 - 3.96 3.96 -6.64 -6.64 -1.2 - 7.08 - 0.818 - - - -

Dividend Paid And Capex Coverage Ratio

1.93 1.93 2.75 2.75 0.801 0.801 4.49 4.49 0.486 0.486 1.39 2.28 0.693 0.996 - 3.37 - -1.43 - 0.922 3.78 3.78 -1.1 -1.1 0.887 0.887 2.49 -0.254 -0.153 -1.77 2.75 -12.2 0.201 - 3.96 3.96 -6.64 -6.64 -1.2 - 7.08 - 0.818 - - - -

Price To Free Cash Flows Ratio, P/FCF

210 K 210 K 47.7 K 47.7 K -877 K -877 K 102 K 102 K -266 K -307 K 151 122 K -170 -26.6 M - 59 K - -14.8 K - -173 K 60.2 K 62.1 K -210 K -243 K -139 K -133 K 35.6 -15.3 -6 K -25.3 K 15.1 -15.3 - -84.1 42.3 K 41.5 K -27.1 K -27 K -32 K - 37.4 K - 87.1 K - - - -

Price To Operating Cash Flows Ratio, P/OCF

101 K 101 K 30.4 K 30.4 K 218 K 218 K 79.2 K 79.2 K 281 K 325 K 42.4 68.8 K 75.1 105 K - 41.5 K - -25.1 K - 14.6 K 44.2 K 45.7 K -19.5 K -22.6 K 17.7 K 16.9 K 21.3 -75.8 -45.3 K -39.5 K 9.6 -16.5 - -84.1 31.6 K 31 K -31.2 K -31 K -58.7 K - 32.1 K - 194 K - - - -

Price Cash Flow Ratio, P/CF

101 K 101 K 30.4 K 30.4 K 218 K 218 K 79.2 K 79.2 K 281 K 325 K 42.4 68.8 K 75.1 105 K - 41.5 K - -25.1 K - 14.6 K 44.2 K 45.7 K -19.5 K -22.6 K 17.7 K 16.9 K 21.3 -75.8 -45.3 K -39.5 K 9.6 -16.5 - -84.1 31.6 K 31 K -31.2 K -31 K -58.7 K - 32.1 K - 194 K - - - -

Enterprise Value Multiple, EV

59.4 K 59.4 K 60.4 K 60.4 K 85 K 85 K 207 K 207 K 165 K 191 K 117 161 K 34.8 61.1 K 63.9 57.9 K 52 10.8 K 0.017 17.3 K 14.1 K 14.6 K 9.56 K 11 K 66.3 K 63.2 K -21.1 39.6 -49.2 K -39.4 K 415 -29.9 -0.884 -448 -24.4 K -23.9 K -194 K -193 K -72 K -80 K -1.11 M 16.5 173 K 159 K - 37.1 -

Price Fair Value, P/FV

13.2 K 13.2 K 11.6 K 11.6 K 15 K 15 K 20.1 K 20.1 K 24.1 K 27.8 K 35.9 K 33.3 K 12.5 K 12.6 K 14.3 K 13.2 K 8.7 K 4.05 K 9.87 10 K 4.37 K 4.52 K 22.1 K 25.5 K 6.13 K 5.84 K 16.8 7.31 8.22 K 8.06 K 8.8 8.57 - 7.1 2.72 K 2.67 K 1.97 K 1.96 K 2.43 K 2.7 K 2.38 K 1.43 4.15 K 1.7 K - 1.41 -

Alle Zahlen in RUB-Währung

Multiplikatoren sind ein wichtiges Instrument der Finanzanalyse für das Unternehmen Институт стволовых клеток человека, das es Investoren und Analysten ermöglicht, den Unternehmenswert und die Investitionsattraktivität schnell anhand des Verhältnisses von Marktindikatoren zu den finanziellen Ergebnissen des Unternehmens zu bewerten. Im Wesentlichen drücken Multiplikatoren aus, wie der Markt das Unternehmen im Verhältnis zu seinem Gewinn, Umsatz, Eigenkapital oder anderen wichtigen Kennzahlen bewertet.

Vorteile der Verwendung von Finanzkennzahlen
  • Vereinfachte Datenanalyse
    Finanzkennzahlen verwandeln große Mengen an Buchhaltungsdaten in kompakte und leicht interpretierbare Indikatoren, was die Beurteilung des Unternehmenszustands erheblich vereinfacht.
  • Vergleichbarkeit zwischen Unternehmen
    Multiplikatoren standardisieren Finanzkennzahlen und ermöglichen so einen objektiven Vergleich von Unternehmen unterschiedlicher Größe, Branche und Marktkapitalisierung.
  • Erkennung von Trends und Problemen
    Die regelmäßige Analyse von Kennzahlen hilft, die Entwicklung der finanziellen Gesundheit zu verfolgen, Stärken und Schwächen des Geschäfts sowie potenzielle Risiken zu identifizieren.
  • Entscheidungsunterstützung
    Finanzielle Multiplikatoren dienen Investoren, Gläubigern und der Unternehmensführung als wichtiges Instrument bei Investitions-, Kredit- und Managemententscheidungen.
  • Beschleunigte Bewertung der Investitionsattraktivität
    Mit Hilfe von Kennzahlen können schnell wichtige Leistungs-, Liquiditäts- und Finanzstabilitätsindikatoren bestimmt werden, was eine zügige Bewertung der Attraktivität von Unternehmen für Investitionen ermöglicht.

Die Verwendung von Multiplikatoren ermöglicht den Vergleich von Unternehmen, auch wenn sie sich in Größe oder Branche unterscheiden, da sie Finanzdaten in für die Analyse geeignete Kennzahlen standardisieren. Dies ist besonders nützlich zur Bewertung von Unternehmen, bei denen eine direkte Analyse der Finanzberichte komplex sein kann oder tiefgehendes Fachwissen erfordert.

Finanzkennzahlen anderer Aktien in der Pharmaeinzelhändler

Name Preis % 24h Marktkapitalisierung Land
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada